Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ProQR Announces First Quarter 2021 Operating and Financial Results
ProQR Therapeutics N.V.May 6, 2021 GMT Phase 2/3 pivotal
Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retinitis pigmentosa, with plans to advance the program into two pivotal Phase 2/3 trials before year end
Exclusive worldwide license and discovery collaboration for non-ophthalmic target with Yarrow Biotechnology, an RTW Investments, LP incubated company
Strengthened balance sheet with $103.5 million gross proceeds from public offering
Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
- Phase 3 HDV D-LIVR (Lonafarnib) 75% Enrolled; Full Enrollment Planned in 2021
- Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021
- Phase 3 COVID-19 TOGETHER Platform Study to Include Lambda Arm
- $3.6M U.S. Zokinvy® Net Sales in Q1 2021
News provided by
Share this article
Share this article
PALO ALTO, Calif., May 6, 2021 /PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported its first quarter 2021 financial results and provided a business update. The Phase 3 D-LIVR study is now 75% enrolled, and by year-end we expect to complete enrollment of this landmark global study advancing Lonafarnib, the only oral agent in development for HDV, setting the stage for Week 48 end of treatment data in 2022, sa
Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retinitis pigmentosa, with plans to advance the program into two pivotal Phase 2/3 trials before year end
Exclusive worldwide license and discovery collaboration for non-ophthalmic target with Yarrow Biotechnology, an RTW Investments, LP incubated company
Strengthened balance sheet with $103.5 million gross proceeds from public offering LEIDEN, Netherlands & CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its financial and operating results for the first quarter ended March 31, 2021 and provided a business update.
Binance May Add Stock Tokens Coinbase (COIN), after Tesla (TSLA), Also Reports Record-Breaking BNB Token Burn
Leading crypto exchange
Binance notes in its weekly report that it completed a record-breaking Binance Coin (BNB) token burn.
The weekly report (April 10 – 16, 2021) from Binance reveals that the digital assets firm burned “a record $593 million in BNB.” The digital currency platform also introduced stock tokens.
As mentioned in the update from Binance:
“Record-breaking BNB burn. For our 15th quarterly BNB Burn (January to March 2021), Binance burned a total of 1,099,888 BNB, equivalent to $595,314,380 worth of tokens.”
The report from Binance also revealed that they’ve added
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020 pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.